-
Roth Remains Positive on Concert Pharma (CNCE) Following Equity Offering; Affirms 'Buy' Rating
-
Concert Pharmaceuticals Announces Completion of Public Offering
-
Concert Pharma (CNCE) Prices 3.3M Common Stock Offering at $15.15/Share
-
Concert Pharmaceuticals Announces Pricing of Public Offering
-
Roth Trims Price Target on Concert (CNCE) to $21; CTP-354 Phase II Delayed on Toxicity Signal
-
Roth Comments on Concert's (CNCE) Initiation of CTP-730 Phase 1
-
Roth Keeps Concert Pharma (CNCE) at 'Buy'; AVP-923 Phase 2 Data is Encouraging (AVNR)
-
Roth Keeps Concert Pharma (CNCE) at Buy; Making Good Progress with Clinical Programs
-
Streetinsider.com's Hot Lunchtime Reads 07/16: (AAPL) (MCP) (MNGA) (YHOO)
-
Roth Capital Encouraged by Removal of CTP-354 Clinical Hold; Has Concert Pharma (CNCE) at 'Buy'
-
Streetinsider.com's Hot Lunchtime Reads 07/08: (PETM) (AAPL) (CNCE) (MSFT)
-
Roth Capital Keeps Concert Pharma (CNCE) at 'Buy'; SPA Filing is Sign of Confidence in CTP-499
-
Roth Capital Starts Concert Pharmaceuticals (CNCE) at Buy
-
Concert Pharmaceuticals (CNCE) IPO Jumps Higher
-
Concert Pharmaceuticals (CNCE) Files $74.75M IPO

